Recent Publications

• •Kenneth S. Wilson, Laurie H. Sehn, Brian Berry, Mukesh Chhanabhai, Catherine A. Fitzgerald, Karamjit K. Gill, Richard Klasa, Brian Skinnider, Judy Sutherland, Joseph M. Connors, Randy D. Gascoyne.  CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma.  Leukemia and Lymphoma 2007; 48(6):1102-9.
• •Laurie H. Sehn, Brian Berry, Mukesh Chhanabhai, Catherine Fitzgerald, Karamjit Gill, Paul Hoskins, Richard Klasa, Kerry J. Savage, Tamara Shenkier, Judy Sutherland, Randy D. Gascoyne, and Joseph M. Connors. The Revised International Prognostic Index (R-IPI) is a Better Predictor of Outcome than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP.  Blood 2007; 109(5):1857-61.
• •Sehn L.H., Donaldson J., Filewich A., Fitzgerald C., Gill K.K., Runzer N., Searle B., Souliere S., Spinelli J.J., Sutherland J., and Connors J.M. Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 2007; 109(10): 4171-73.
• •Wilson K.S., Fitzgerald C.A., Barnett J. B., Gill S., and Khoo K.E. Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia cancer agency experience. Cancer Investigation 2007; 25(8):711-14.
• •Kenneth S. Wilson, Laurie H. Sehn, Brian Berry, Mukesh Chhanabhai, Catherine A. Fitzgerald, Karamjit K. Gill, Richard Klasa, Brian Skinnider, Judy Sutherland, Joseph M. Connors, Randy D. Gascoyne.  CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma.  Leukemia and Lymphoma 2007; 48(6):1102-9.
• •Laurie H. Sehn, Brian Berry, Mukesh Chhanabhai, Catherine Fitzgerald, Karamjit Gill, Paul Hoskins, Richard Klasa, Kerry J. Savage, Tamara Shenkier, Judy Sutherland, Randy D. Gascoyne, and Joseph M. Connors. The Revised International Prognostic Index (R-IPI) is a Better Predictor of Outcome than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP.  Blood 2007; 109(5):1857-61.
• •Sehn L.H., Donaldson J., Filewich A., Fitzgerald C., Gill K.K., Runzer N., Searle B., Souliere S., Spinelli J.J., Sutherland J., and Connors J.M. Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 2007; 109(10): 4171-73.
• •Wilson K.S., Fitzgerald C.A., Barnett J. B., Gill S., and Khoo K.E. Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia cancer agency experience. Cancer Investigation 2007; 25(8):711-14.
• •Lim H. J., Gill S., Speers C., Melosky B., Barnett J., Fitzgerald C., O’Reilly S., Kennecke H.  Impact of irinotecan and oxaliplatin on overall survival in patients with metastatic colorectal cancer: A population-based study. J Oncol Pract 2009; 5(4): 153-8.
• •Lim H. J., Gill S., Speers C., Melosky B., Barnett J., Fitzgerald C., O’Reilly S., Kennecke H.  Impact of irinotecan and oxaliplatin on overall survival in patients with metastatic colorectal cancer: A population-based study. J Oncol Pract 2009; 5(4): 153-8.